Integra Non Currrent Assets Other vs Total Stockholder Equity Analysis
IART Stock | USD 27.54 0.05 0.18% |
Integra LifeSciences financial indicator trend analysis is infinitely more than just investigating Integra LifeSciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Integra LifeSciences is a good investment. Please check the relationship between Integra LifeSciences Non Currrent Assets Other and its Total Stockholder Equity accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Non Currrent Assets Other vs Total Stockholder Equity
Non Currrent Assets Other vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Integra LifeSciences Non Currrent Assets Other account and Total Stockholder Equity. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Integra LifeSciences' Non Currrent Assets Other and Total Stockholder Equity is -0.34. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Integra LifeSciences Holdings, assuming nothing else is changed. The correlation between historical values of Integra LifeSciences' Non Currrent Assets Other and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Integra LifeSciences Holdings are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Non Currrent Assets Other i.e., Integra LifeSciences' Non Currrent Assets Other and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | -0.34 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Integra LifeSciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Integra LifeSciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Integra LifeSciences' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 442.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 339.5 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 944.6M | 970.3M | 888.4M | 458.0M | Total Revenue | 1.5B | 1.6B | 1.5B | 1.6B |
Integra LifeSciences fundamental ratios Correlations
Click cells to compare fundamentals
Integra LifeSciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Integra LifeSciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.3B | 3.6B | 3.8B | 3.9B | 3.8B | 4.0B | |
Other Current Liab | 156.2M | 182.1M | 213.1M | 158.8M | 176.3M | 185.1M | |
Total Current Liabilities | 331.3M | 401.0M | 340.0M | 320.9M | 307.0M | 158.9M | |
Total Stockholder Equity | 1.4B | 1.5B | 1.7B | 1.8B | 1.6B | 1.7B | |
Property Plant And Equipment Net | 431.9M | 371.2M | 396.2M | 459.6M | 496.4M | 521.2M | |
Net Debt | 1.3B | 1.2B | 1.1B | 1.2B | 1.4B | 1.5B | |
Retained Earnings | 398.6M | 532.3M | 698.6M | 879.1M | 946.9M | 994.2M | |
Accounts Payable | 113.1M | 54.6M | 61.8M | 102.1M | 92.3M | 96.9M | |
Cash | 198.9M | 470.2M | 513.4M | 456.7M | 276.4M | 290.2M | |
Non Current Assets Total | 2.4B | 2.4B | 2.6B | 2.7B | 2.7B | 2.9B | |
Non Currrent Assets Other | 11.2M | 11.3M | 10.0M | (510.2M) | 26.0M | 27.3M | |
Cash And Short Term Investments | 198.9M | 470.2M | 513.4M | 456.7M | 309.1M | 324.6M | |
Net Receivables | 275.3M | 225.5M | 231.8M | 263.5M | 259.3M | 272.3M | |
Common Stock Shares Outstanding | 86.5M | 85.2M | 85.5M | 83.5M | 80.3M | 67.2M | |
Liabilities And Stockholders Equity | 3.3B | 3.6B | 3.8B | 3.9B | 3.8B | 4.0B | |
Non Current Liabilities Total | 1.6B | 1.7B | 1.8B | 1.8B | 1.9B | 2.0B | |
Inventory | 316.1M | 310.1M | 317.4M | 324.6M | 389.6M | 409.1M | |
Other Current Assets | 67.9M | 231.4M | 91.1M | 116.8M | 100.0M | 51.5M | |
Other Stockholder Equity | 1.1B | 1.1B | 1.0B | 914.1M | 655.2M | 467.2M | |
Total Liab | 1.9B | 2.1B | 2.1B | 2.1B | 2.2B | 2.3B | |
Property Plant And Equipment Gross | 431.9M | 371.2M | 711.1M | 789.3M | 863.8M | 907.0M | |
Total Current Assets | 858.2M | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B | |
Accumulated Other Comprehensive Income | (76.4M) | (74.1M) | (45.2M) | 10.3M | (15.1M) | (15.9M) | |
Intangible Assets | 1.0B | 989.4M | 1.1B | 1.1B | 1.1B | 1.1B | |
Short Long Term Debt Total | 1.5B | 1.7B | 1.7B | 1.6B | 1.7B | 1.8B | |
Common Stock Total Equity | 887K | 893K | 896K | 905K | 1.0M | 528.7K | |
Short Term Investments | 1.5M | 4.7M | 12K | 16.7M | 32.7M | 34.3M | |
Short Term Debt | 57.3M | 159.1M | 59.8M | 52.7M | 29.8M | 28.3M | |
Common Stock | 887K | 893K | 896K | 905K | 909K | 547.5K | |
Other Liab | 116.1M | 131.2M | 135.9M | 201.8M | 232.1M | 243.7M | |
Other Assets | 27.3M | 168.6M | 3.8B | 63.2M | 72.6M | 69.0M | |
Long Term Debt | 1.2B | 1.4B | 1.4B | 1.3B | 1.5B | 749.7M | |
Treasury Stock | (119.9M) | (235.1M) | (234.4M) | (362.9M) | (326.6M) | (310.2M) | |
Property Plant Equipment | 337.4M | 287.5M | 311.7M | 311.3M | 358.0M | 375.9M | |
Current Deferred Revenue | 4.8M | 5.3M | 5.3M | 7.3M | 8.5M | 5.3M | |
Good Will | 954.3M | 932.4M | 1.0B | 1.0B | 1.1B | 1.1B | |
Net Tangible Assets | (569.1M) | (406.9M) | (474.2M) | (361.1M) | (325.0M) | (341.2M) | |
Retained Earnings Total Equity | 398.6M | 532.3M | 698.6M | 879.1M | 1.0B | 1.1B | |
Long Term Debt Total | 1.2B | 1.4B | 1.4B | 1.3B | 1.5B | 1.0B | |
Capital Surpluse | 1.2B | 1.3B | 1.3B | 1.3B | 1.5B | 1.0B |
Pair Trading with Integra LifeSciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integra LifeSciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integra LifeSciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Integra Stock
0.87 | DOCS | Doximity Upward Rally | PairCorr |
0.62 | VEEV | Veeva Systems Class Financial Report 29th of May 2024 | PairCorr |
0.65 | ENSG | Ensign Group | PairCorr |
Moving against Integra Stock
0.88 | HAE | Haemonetics | PairCorr |
0.84 | EHC | Encompass Health Corp | PairCorr |
0.71 | ELV | Elevance Health Financial Report 17th of July 2024 | PairCorr |
0.69 | DVA | DaVita HealthCare | PairCorr |
The ability to find closely correlated positions to Integra LifeSciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Integra LifeSciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Integra LifeSciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Integra LifeSciences Holdings to buy it.
The correlation of Integra LifeSciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Integra LifeSciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Integra LifeSciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Integra LifeSciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Integra Stock analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Integra LifeSciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integra LifeSciences. If investors know Integra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integra LifeSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.60) | Earnings Share 0.51 | Revenue Per Share 19.349 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0383 |
The market value of Integra LifeSciences is measured differently than its book value, which is the value of Integra that is recorded on the company's balance sheet. Investors also form their own opinion of Integra LifeSciences' value that differs from its market value or its book value, called intrinsic value, which is Integra LifeSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integra LifeSciences' market value can be influenced by many factors that don't directly affect Integra LifeSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integra LifeSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Integra LifeSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integra LifeSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.